SS-31

The SS-31 evidence base cited here is 9 sources — 3 clinical, 3 preclinical, 1 review. Its strongest evidence is human — 3 clinical studies, most recently 2020 ("Effects of Elamipretide on Left Ventricular Function in Patients With He…"). Regulatory status: FDA-approved (Barth Syndrome).

Within the longevity space these three peptides are often discussed together because they target genuinely different aging pathways — useful for understanding where SS-31 fits.

The three are complementary, not interchangeable: SS-31 addresses the energy/mitochondrial axis, Epithalon the telomere/circadian axis, and Thymosin Alpha-1 the immune axis. SS-31 is the only one of the three with an FDA approval (narrowly, for Barth syndrome).

• SS-31 (Elamipretide; also Bendavia / MTP-131) is a synthetic aromatic-cationic tetrapeptide (D-Arg-Dmt-Lys-Phe-NH₂) that selectively concentrates in mitochondria — 1,000–5,000× the surrounding cytosol — to protect mitochondrial structure rather than scavenge free radicals after the fact.
• Its core mechanism is binding and stabilizing cardiolipin, the inner-membrane phospholipid that scaffolds the electron-transport-chain complexes — preserving ETC architecture, improving ATP output, and cutting reactive-oxygen-species generation at the source.
• Landmark fact: on September 19, 2025 the FDA granted accelerated approval to elamipretide (brand FORZINITY) for Barth syndrome in patients ≥30 kg — the FIRST FDA-approved therapy for any mitochondrial disease.

SS-31 (Elamipretide) is a first-in-class mitochondria-targeting peptide built to address the root cause of diseases driven by mitochondrial dysfunction, rather than their downstream symptoms. It is a four-amino-acid peptide engineered to selectively accumulate inside mitochondria, where it stabilizes the inner-membrane phospholipid cardiolipin and, with it, the machinery that generates cellular energy.

It stands apart from most peptides discussed in the longevity/performance space in two ways: it acts at the level of cellular bioenergetics (not growth-factor or hormonal pathways), and it has a real clinical-trial record — culminating in FDA accelerated approval in September 2025 (as FORZINITY) for Barth syndrome, the first approved therapy for any mitochondrial disease.

Approval is narrow (Barth syndrome only); everything else remains investigational, and the cardiac trials were mixed. Everything below is research context synthesized from the published literature — not medical guidance, and not a self-administration protocol.

SS-31 (Elamipretide, Bendavia, MTP-131) is a synthetic aromatic-cationic tetrapeptide, D-Arg-Dmt-Lys-Phe-NH₂ (molecular formula C32H49N9O5), developed by Stealth BioTherapeutics. Its structure lets it cross membranes and concentrate selectively within mitochondria — reportedly 1,000–5,000× the cytosolic level — rather than distributing broadly through the cell.

The molecular rationale centers on cardiolipin, a phospholipid found almost exclusively in the inner mitochondrial membrane that organizes the electron-transport-chain (ETC) complexes for efficient ATP generation. In aging, disease, and ischemic injury, cardiolipin becomes oxidized/peroxidized, destabilizing those complexes and impairing energy production. SS-31 binds cardiolipin through electrostatic and hydrophobic interactions, preventing its oxidation and preserving ETC architecture.

This makes SS-31 different both from conventional antioxidants (which scavenge radicals after they form) and from most biohacking peptides (which act through growth-factor or hormonal pathways) — it operates upstream, at the structural level of mitochondrial bioenergetics.

Outside the approved Barth-syndrome indication there are no FDA-approved dosing guidelines. The following come from published trial protocols and community reports, included for research context only — not as instructions for use.

No published data exists for subcutaneous self-administration in healthy individuals, and the Phase 3 MMPOWER-3 trial did NOT meet its primary endpoints for the general PMM population. Trials used continuous dosing (up to ~36 weeks) without apparent tolerance; community cycling (e.g., 8 on / 4 off) has no established scientific necessity.

Reported effects split into an immediate arm (cardiolipin stabilization improving current mitochondrial efficiency) and a slower structural arm (PGC-1α-driven biogenesis over months).

SS-31 has a clinical dataset that, while modest in size, is substantially more robust than most peptides used in the biohacking community — and now includes an FDA approval.

Honest read: the clinical evidence is mixed — the big cardiac and general-PMM endpoints were missed — but the mechanism is well-characterized, subgroups and the Barth data show genuine signal, and the FDA approval (for the disease most directly tied to cardiolipin) is real validation. Efficacy in healthy, non-diseased humans remains unproven.

SS-31's mitochondria-specific mechanism is genuinely complementary to several cellular-energy compounds — unusual among peptide stacks, which often lack mechanistic rationale. Formal interaction studies are absent for all combinations; research context, not protocol advice.

• SS-31 + NAD+ precursors (NMN / NR) — arguably the most synergistic: NAD+ is the key ETC electron carrier and a sirtuin substrate; SS-31 optimizes ETC structure while precursors raise carrier availability, addressing both structural and substrate limits of aging mitochondria.
• SS-31 + CoQ10 / ubiquinol — CoQ10 shuttles electrons between Complexes I/II and III; SS-31 preserves the protein complexes through which it operates — complementary carrier-availability vs structural-context roles.
• SS-31 + PQQ — both appear to activate PGC-1α biogenesis, so the combination may be additive/synergistic, though direct evidence is lacking.
• SS-31 + BPC-157 — for post-injury/surgical contexts pairing mitochondrial support with angiogenesis and tissue repair; no formal research examines it.

SS-31 is supplied as a lyophilized powder requiring reconstitution before subcutaneous use. The following reflects general laboratory peptide handling only.

• Bring vial to room temperature; use bacteriostatic water (0.9% benzyl alcohol); add water slowly down the interior vial wall (not jetted onto the powder) and swirl gently until clear and colorless — do not shake.
• Common ratio: 40 mg + 40 mL bacteriostatic water = 1 mg/mL.
• Lyophilized powder: store at −20°C long-term (2–8°C for several months); protect from light and moisture.
• Reconstituted solution: store at 2–8°C, use within ~28 days; discard if cloudy, discolored, or particulate. Vials reconstituted with non-preserved sterile water should not be stored.

Published clinical trials show a favorable safety profile, with most adverse events mild and serious-event rates consistent with placebo.

No serious adverse events have been definitively attributed to SS-31 in published trials, and no carcinogenicity has emerged preclinically. But long-term data in healthy (non-diseased) people doesn't exist, and the favorable profile came from monitored settings with pharmaceutical-grade material — not research-chemical supply chains, where contamination/purity risks are separate from the compound itself.

SS-31's regulatory status changed materially in 2025. For a broader overview of where research peptides sit legally, see the peptide legality guide.

• September 19, 2025: FDA accelerated approval of elamipretide as FORZINITY for Barth syndrome in patients ≥30 kg — the first FDA-approved therapy for any mitochondrial disease.
• Supporting designations: Fast Track (Barth syndrome + PMM), Orphan Drug (Barth), Rare Pediatric Disease (Barth, with Priority Review Voucher eligibility).
• Not FDA-approved for any other indication — heart failure, PMM, and age-related/longevity use remain investigational.
• Not DEA-scheduled. International status (Australia, Canada, UK, EU) differs from the US framework.

Approval is specific to Barth syndrome (as FORZINITY). Research-grade SS-31 sold for any other use is for laboratory research only and is not intended for human use.

SS-31 is not currently named on the WADA Prohibited List — a contrast with BPC-157, which received an explicit ban in 2022. But athletes should be cautious: WADA's S0 catch-all prohibits non-approved pharmacological substances used for performance enhancement, and SS-31's potential to improve exercise capacity, mitochondrial efficiency, and recovery could attract future scrutiny; individual federations may also prohibit investigational drugs more broadly. 'Not currently banned' does not guarantee future status — tested athletes in high-consequence sports should clear any use with their anti-doping authority first.

All citations link to the original source (PubMed, journal site, or regulatory filing). Independent research database — no vendor influence on what's cited.